Predictive factors associated with VEN response remain elusive but there is growing evidence to show that NPM1 and IDH mutated AML patients have a good outcome, whereas AML patients with mutations in TP53 or RAS pathway genes have a poor outcome [7,8,9,10,11]. Here, IDH2 is linked to acute myeloid leukemia.